Literature DB >> 1366927

The advent of recombinant pertussis vaccines.

W N Burnette1.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 1366927     DOI： 10.1038/nbt1190-1002

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN： 0733-222X


× No keyword cloud information.
  4 in total

1.  Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli.

Authors:  W N Burnette; J L Arciniega; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity.

Authors:  W N Burnette; V L Mar; B W Platler; J D Schlotterbeck; M D McGinley; K S Stoney; M F Rohde; H R Kaslow
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

3.  Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.

Authors:  J L Arciniega; R D Shahin; W N Burnette; T D Bartley; D W Whiteley; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 4.  Progress with a recombinant whooping cough vaccine: a review.

Authors:  W N Burnette; V L Mar; D W Whiteley; T D Bartley
Journal:  J R Soc Med       Date:  1992-05       Impact factor: 18.000
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.